Evidence map›Paper›PMID 33491917›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2021

Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.

Scott Ayton, Stuart Portbury, Pawel Kalinowski, Puja Agarwal, Ibrahima Diouf, Julie A Schneider, Martha Clare Morris, Ashley I Bush

Open access · greenAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 149 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Ferroptotic neurodegeneration and diet: a narrative review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Aberrant Mitochondrial Metabolism in Alzheimer's Disease Links Energy Stress with Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  18. Review
  19. Article
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Scott AytonMelbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, Australia.
Stuart PortburyMelbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, Australia.
Pawel KalinowskiMelbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, Australia.
Puja AgarwalRush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois, USA.
Ibrahima DioufMelbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, Australia.
Julie A SchneiderRush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Martha Clare MorrisRush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois, USA.
Ashley I BushMelbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, Australia.ORCID 0000-0001-8259-9069
The University of Melbourne · AURush University Medical Center · US

Funding

EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Neuropathologic-Epidemiological Study of Metallomics and Alzheimer's DiseaseR01AG054057 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Julie A. Schneider · 2022 to 2026
$3.0M
Neuropathologic-Epidemiological Study of Metallomics and Alzheimer's DiseaseRF1AG054057 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BUSH, ASHLEY I, SCHNEIDER, JULIE A. · 2016 to 2016
$2.8M
NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG054057NIA NIH HHS RF1 AG054057NIH HHS R01AG017917NIH HHS R21E2021290NIH HHS RF1AG054057
6 · The paper itself

Abstract

objectiveThis paper is a proposal for an update of the iron hypothesis of Alzheimer's disease (AD), based on large-scale emerging evidence.

backgroundIron featured historically early in AD research efforts for its involvement in the amyloid and tau proteinopathies, APP processing, genetics, and one clinical trial, yet iron neurochemistry remains peripheral in mainstream AD research. Much of the effort investigating iron in AD has focused on the potential for iron to provoke the onset of disease, by promoting proteinopathy though increased protein expression, phosphorylation, and aggregation. NEW/UPDATED HYPOTHESIS: We provide new evidence from a large post mortem cohort that brain iron levels within the normal range were associated with accelerated ante mortem disease progression in cases with underlying proteinopathic neuropathology. These results corroborate recent findings that argue for an additional downstream role for iron as an effector of neurodegeneration, acting independently of tau or amyloid pathologies. We hypothesize that the level of tissue iron is a trait that dictates the probability of neurodegeneration in AD by ferroptosis, a regulated cell death pathway that is initiated by signals such as glutathione depletion and lipid peroxidation. MAJOR CHALLENGES FOR THE HYPOTHESIS: While clinical biomarkers of ferroptosis are still in discovery, the demonstration of additional ferroptotic correlates (genetic or biomarker derived) of disease progression is required to test this hypothesis. The genes implicated in familial AD are not known to influence ferroptosis, although recent reports on APP mutations and apolipoprotein E allele (APOE) have shown impact on cellular iron retention. Familial AD mutations will need to be tested for their impact on ferroptotic vulnerability. Ultimately, this hypothesis will be substantiated, or otherwise, by a clinical trial of an anti-ferroptotic/iron compound in AD patients. LINKAGE TO OTHER MAJOR THEORIES: Iron has historically been linked to the amyloid and tau proteinopathies of AD. Tau, APP, and apoE have been implicated in physiological iron homeostasis in the brain. Iron is biochemically the origin of most chemical radicals generated in biochemistry and thus closely associated with the oxidative stress theory of AD. Iron accumulation is also a well-established consequence of aging and inflammation, which are major theories of disease pathogenesis.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloidApolipoproteins EBrainCohort StudiesFemaleHumansIronMalePhosphorylationtau ProteinsAmyloidApolipoproteins EIrontau ProteinsAlzheimer's diseasecognitive declineironneurodegenerationpathology

Identifiers

PMID33491917
PMCPMC9701539
OpenAlexW3122909401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.